Maculaser develops novel medical technology for treatment of common retinal diseases, including diabetic macular edema and dry age-related macular degeneration. The core of the company’s innovation is the precise temperature control of the macula during non-damaging laser treatments; a potential game changer in the practice how retinal diseases, with over 200B EUR direct health care costs, are being treated in the future.
-
- Founding year:
2020
-
- Development phase:
Beta-testing
-
- Funding:
Seed / A round
-
- Website:
-
- Contact person info:
jani.tirronen(at)maculaser.com
-
- Team members:
5
-
- Article:
Read an article about Maculaser.
Recent Comments